Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia
- PMID: 22173318
- DOI: 10.1016/j.expneurol.2011.11.038
Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia
Abstract
Background and purpose: The Cilostazol Stroke Prevention Study II has shown a similar efficacy in stroke prevention but markedly fewer hemorrhagic events with the phosphodiesterase inhibitor cilostazol versus aspirin. The purpose of this study is therefore to investigate how cilostazol affects cerebral hemodynamics and whether it prevents hemorrhagic transformation induced by recombinant tissue plasminogen activator (rtPA) in a mouse model of focal ischemia/reperfusion. Particular emphasis will be placed on the plasma-microvessel interface.
Methods: After receiving food containing 0.3% cilostazol or standard food for 7 days, adult C57BL/6J mice were subjected to middle cerebral artery occlusion/reperfusion with or without rtPA (10mg/kg) intravenously administered prior to reperfusion. Cerebral blood flow was monitored at several time points by laser speckle imaging in the 24 hour period post reperfusion, before neurobehavioral and histological assessment. The long-term effect of cilostazol on cerebral ischemia was analyzed in the non-rtPA cohort.
Results: In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of adhesion molecules (P-selectin and intercellular adhesion molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after cerebral ischemia/reperfusion in the acute phase. Cilostazol significantly reduced mortality rate and improved motor function at 7 days post-ischemia/reperfusion. In the rtPA cohort, cilostazol significantly suppressed edema formation and hemorrhagic transformation with reduced density of microglial cells positive for matrix metalloproteinase-9 in the cerebral cortex and the striatum. In both cohorts, cilostazol significantly suppressed focal no-reflow, mitigated cerebral infarct, and improved neurological outcome.
Conclusions: Cilostazol may possess protective properties against cerebral ischemic injury by preventing no-reflow and hemorrhagic transformation, via maintenance of microvascular integrity.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.PLoS One. 2010 Dec 6;5(12):e15178. doi: 10.1371/journal.pone.0015178. PLoS One. 2010. PMID: 21151895 Free PMC article.
-
Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion.Stroke. 2003 Aug;34(8):2025-30. doi: 10.1161/01.STR.0000083051.93319.28. Epub 2003 Jul 10. Stroke. 2003. PMID: 12855824
-
Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage.Neurosci Lett. 2009 Mar 13;452(2):156-61. doi: 10.1016/j.neulet.2009.01.039. Epub 2009 Jan 21. Neurosci Lett. 2009. PMID: 19383431
-
[Protective effects of cilostazol against transient focal cerebral ischemia and hemorrhagic transformation].Yakugaku Zasshi. 2011 Apr;131(4):513-21. doi: 10.1248/yakushi.131.513. Yakugaku Zasshi. 2011. PMID: 21467790 Review. Japanese.
-
Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives.J Pharmacol Sci. 2016 Jul;131(3):155-61. doi: 10.1016/j.jphs.2016.04.023. Epub 2016 May 3. J Pharmacol Sci. 2016. PMID: 27381422 Review.
Cited by
-
No-reflow after recanalization in ischemic stroke: From pathomechanisms to therapeutic strategies.J Cereb Blood Flow Metab. 2024 Jun;44(6):857-880. doi: 10.1177/0271678X241237159. Epub 2024 Feb 29. J Cereb Blood Flow Metab. 2024. PMID: 38420850 Review.
-
Emerging diagnostic markers and therapeutic targets in post-stroke hemorrhagic transformation and brain edema.Front Mol Neurosci. 2023 Dec 21;16:1286351. doi: 10.3389/fnmol.2023.1286351. eCollection 2023. Front Mol Neurosci. 2023. PMID: 38178909 Free PMC article. Review.
-
Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial.JAMA Netw Open. 2023 Dec 1;6(12):e2344938. doi: 10.1001/jamanetworkopen.2023.44938. JAMA Netw Open. 2023. PMID: 38048134 Free PMC article. Clinical Trial.
-
"No-reflow" phenomenon in acute ischemic stroke.J Cereb Blood Flow Metab. 2024 Jan;44(1):19-37. doi: 10.1177/0271678X231208476. Epub 2023 Oct 19. J Cereb Blood Flow Metab. 2024. PMID: 37855115 Review.
-
Light Alcohol Consumption Promotes Early Neurogenesis Following Ischemic Stroke in Adult C57BL/6J Mice.Biomedicines. 2023 Apr 2;11(4):1074. doi: 10.3390/biomedicines11041074. Biomedicines. 2023. PMID: 37189692 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical